We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CBER unveiled its guidance agenda for the 2020, including planned draft guidances on gene therapy for neurodegenerative diseases, CAR-T cell therapies and genome editing.